Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
about
Microbiota and Neurological Disorders: A Gut Feeling.Gastrointestinal stem cells in health and disease: from flies to humansCytokine-Induced Modulation of Colorectal CancerDrug Discovery via Human-Derived Stem Cell OrganoidsAntagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancerHigh-content molecular profiling of T-cell therapy in oncologyImplication of the intestinal microbiome in complications of cirrhosisHost-Microbiome Interaction and Cancer: Potential Application in Precision MedicineThe Gut Microbiome as Therapeutic Target in Central Nervous System Diseases: Implications for StrokeThe Impact of the Gut Microbiota on Drug Metabolism and Clinical OutcomeRole of the Microbiota in Colorectal Cancer: Updates on Microbial Associations and Therapeutic ImplicationsGlutamine-Induced Secretion of Intestinal Secretory Immunoglobulin A: A Mechanistic PerspectivePD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinationsCross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatmentGut microbiota and colorectal cancer.Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis.The intestinal microbiome and surgical disease.Pharmacogenomics of off-target adverse drug reactions.Metagenomics and Single-Cell Omics Data Analysis for Human Microbiome Research.Immune Checkpoint in Glioblastoma: Promising and ChallengingFaecal microbiota transplantation: Where did it start? What have studies taught us? Where is it going?Role of CD152 genetic polymorphisms in the susceptibility to breast cancer.Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.Neutrophils in the tumor microenvironment: trying to heal the wound that cannot heal.Microbiota, Inflammation and Colorectal Cancer.Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy.The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study.Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.Manipulation of Innate and Adaptive Immunity through Cancer Vaccines.The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists.IMMUNOTHERAPY. Could microbial therapy boost cancer immunotherapy?Tumour immunology: Intestinal bacteria are in command.A 'fit' microbiota to potentiate cancer immunotherapyThe role of microbiota in cancer therapy.Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis.The complex interplay of diet, xenobiotics, and microbial metabolism in the gut: Implications for clinical outcomes.Signaling in Host-Associated Microbial Communities.The microbial pharmacists within us: a metagenomic view of xenobiotic metabolismRecognizing that the microbiome is part of the human immune system will advance treatment of both cancer and infections.The metabolic role of the gut microbiota in health and rheumatic disease: mechanisms and interventions.
P2860
Q24570085-18DCC151-14BF-4CC4-B482-05EB21B62346Q26750514-ECE0729C-D55E-43B9-A26D-9EC9D7A29321Q26752374-94203916-6126-491A-8E7A-30A57EF090EEQ28066424-9D27C34B-044E-4D5A-94CC-4FF820F05AE5Q28066532-04869B4D-D5F3-4B8D-BE86-9F6B6F9A52B3Q28066792-7C1BDC72-2EF0-452B-A49F-DCAE18CF0F1EQ28068832-B70102AA-4835-44D5-BF0B-16BBDB96F721Q28069401-23BBFB1B-1294-429E-BE80-8F8D50B351F6Q28069455-E9B511BF-29ED-4096-8CD9-EA0CBCDF7E75Q28071938-115110E2-021C-4E3D-8A5F-6ABBED334C13Q28073131-BF45A513-C231-41AF-8629-37D063D28EEFQ28073867-4283A1CB-726C-4610-808A-714A03D054DCQ28075712-271B073A-F363-4B14-B4EE-2E1B0E51E3F8Q28076294-2FB23BDC-9A2E-414B-B16C-4C6B636264C7Q30239806-069F89A3-DDA6-44EF-9A67-5CD13F39A42BQ30244608-CEDE158D-378B-471F-9F88-45FC23C79B5EQ30248605-B16E7BA4-514A-4C12-BF29-41A2FAF005CAQ30400366-46CDF7D6-8AFA-4079-8798-05400BA50E4BQ31140588-5D9C4571-BEDC-4E62-8427-9C60D0B2B043Q33650058-E9253D33-ED88-4672-8049-AF6778A60366Q33686153-044538C2-F5EF-4218-91AD-861EC6B59403Q33688783-05B21D21-4E23-4E0E-8C10-E90EB3BA35C2Q33699687-2C058A83-6BBE-4F55-9B58-62ACBA1381F6Q33816141-9FEFA78E-C657-49C6-832D-0565344F323AQ33839116-D44B7FF2-3A00-4611-B0D2-8F4AF7CBFC51Q33883909-00B500E1-06FB-4D38-A287-4852FE3CFCCFQ33918472-CD476DCA-DF89-490B-9788-93454B1E9BA3Q34522172-D047412B-BCCA-46C0-9533-43B665F7ABCFQ34552791-850AFEE1-A866-43F7-A3FE-F91152FDA1C1Q34553267-56CB1E6B-A165-417B-B122-2A68ACB4CF66Q35854335-395FF7E0-27B8-41ED-8D27-3071FD1849E5Q35865880-B0BBB153-F55C-4EA7-9359-91CDFF54A343Q35874071-1749E122-101E-4869-9361-C5C2E5B61EBFQ35906938-767D3CCD-063A-4D01-97EA-DCE7601A31D9Q35912366-CF507F6E-DA43-4E0D-A74D-9931E13682DAQ35947598-0C6ACB13-E7EE-47C0-AAF5-155EE1DAD405Q35953810-830152FA-A552-45CD-B5DF-31DB7F9C2BB9Q35955534-61145243-BECE-4867-9C25-FB7DB59B563AQ35958323-0C3276E8-E8FC-4135-8352-71A7F0F2574BQ36038992-9EEA0795-71A1-44C9-88B9-C2AB9ED72013
P2860
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
@ast
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
@en
type
label
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
@ast
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
@en
prefLabel
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
@ast
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
@en
P2093
P2860
P50
P356
P1433
P1476
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
@en
P2093
Andreas Schlitzer
Antoine Roux
Bertrand Routy
Christina Mateus
Connie P M Duong
David P Enot
Elisabeth Chachaty
Encouse Golden
Florent Ginhoux
Franck Carbonnel
P2860
P304
P356
10.1126/SCIENCE.AAD1329
P407
P50
P577
2015-11-05T00:00:00Z